ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0307

Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes

Sanat Phatak1, Rucha Wagh2, Smita Dhadge2, Sarita Jadhav2, Parth Ladha3, Rishi Nalkande4, Rohan Shah2, Jennifer Ingram5 and Chittaranjan Yajnik2, 1KEM Hospital Research Centre, Pune, Maharashtra, India, 2KEM Hospital Research Centre, Pune, India, 3Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India, 4BJ Government Medical College, Pune, India, 5Duke University Medical Center, Durham, NC

Meeting: ACR Convergence 2024

Keywords: FMF, metabolic syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Hand manifestations (limited joint mobility, [LJM]; flexor tenosynovitis, [FT]; carpal tunnel syndrome, [CTS]; Dupuytren disease, [DD]) are common complications in diabetes. Despite their heterogeneity in presentation, all manifestations share a common pathophysiologic process of pro-fibrotic inflammation in flexor structures. Unifying measures of disease severity across these conditions are lacking. We studied prevalence and severity in diabetes, prediabetes and controls, and assessed the utility of measuring mean metacarpophalangeal joint (MCP) extension in these conditions.

Methods: We studied 2405 adult individuals with Type 1 diabetes (n=291), Type 2 diabetes (n=877), prediabetes (n=326) and non-diabetic controls (n=911). Comprehensive clinical evaluations assessed hand symptoms, signs (Tinel sign, tenosynovial thickening), function (hand grip strength, Duruoz Hand Index, [DHI]).  Mean MCP extension was calculated as an average of maximum passive extension of 2nd-5th finger of each hand, measured by a protractor. A rheumatologist or diabetes specialist opined independently on the manifestation present; skin thickening (ST) was classified when there was no prayer sign.  Data on diabetes duration, medications, complications were collected. We compared mean MCP extension in diabetes versus controls (ANOVA adjusted for age and sex) and in those with hand manifestations versus those without.

Results: Approximately one third patients with diabetes (34% Type 1, 36% Type 2) and prediabetes (31%) had hand involvement, as compared to 24% in controls (Table 1). As a group, mean MCP extension was lower in Type 2, Type 1 and prediabetes when compared with controls (all p< 0.01). Across all groups, Mean MCP extension was hampered in patients with LJM, ST, FT and DD (all p< 0.01 compared to those with no hand manifestations) but not in CTS. (p=0.053) (Table 2). Grip strength was significantly lower only in LJM and CTS but not in the others manifestations. MCP extension angle correlated with DHI (R = 0.17, p< 0.01, Figure 1A) and grip strength (R = 0.26, p< 0.01, Figure 1B); DHI was elevated mainly in those with MCP extension < 30 degrees. (Figure 1). A regression model in the diabetic population (Type 1 and Type 2) showed that Mean MCP angle was associated with diabetes duration (p< 0.01) and microvascular complications (p=0.03) but not insulin use, body mass index (BMI), macrovascular complications, history of frozen shoulder or liver disease.

Conclusion: Our findings underscore the high prevalence of flexor hand manifestations, often asymptomatic, in diabetes and controls. MCP extension is a potential marker of the extent of hand fibrosis in LJM, FT and DD, picking up early involvement without functional limitation. This simple and non-invasive technique offers a quantitative measure of hand involvement that will allow correlations with markers of fibrosis in other organs and as an outcome measure for responses to medical and surgical treatments in these conditions. 

Supporting image 1

Fig 1: Relationship between Metacarpophalangeal joint extension with measures of hand function: Duruoz Hand Index (Fig 1A) and Hand grip strength (fig 1B)

Supporting image 2

Prevalence of flexor fibro-inflammatory hand manifestations across patient groups

Supporting image 3

Mean Metacarpophalangeal (MCP) joint extension and measures of hand function in patients with individual hand manifestations


Disclosures: S. Phatak: Med 2 Measure Pvt Ltd, 8, Proxi Farma Pvt Ltd, 1; R. Wagh: None; S. Dhadge: None; S. Jadhav: None; P. Ladha: None; R. Nalkande: None; R. Shah: None; J. Ingram: None; C. Yajnik: None.

To cite this abstract in AMA style:

Phatak S, Wagh R, Dhadge S, Jadhav S, Ladha P, Nalkande R, Shah R, Ingram J, Yajnik C. Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/mean-metacarpophalangeal-extension-to-clinically-quantify-flexor-fibro-inflammatory-hand-involvement-in-diabetes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mean-metacarpophalangeal-extension-to-clinically-quantify-flexor-fibro-inflammatory-hand-involvement-in-diabetes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology